Gilead Sciences Financial Statements (GILD)
|
|
|
|
Report date
|
|
|
25.02.2021 |
23.02.2022 |
31.12.2022 |
22.02.2023 |
23.02.2024 |
|
12.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
24 689 |
27 305 |
27 281 |
27 281 |
27 116 |
|
28 730 |
|
Operating Income, bln rub |
|
|
7 029 |
7 406 |
7 330 |
7 330 |
7 605 |
|
98.0 |
|
EBITDA, bln rub |
? |
|
4 133 |
11 329 |
6 775 |
8 852 |
10 496 |
|
139.0 |
|
Net profit, bln rub |
? |
|
89.0 |
6 225 |
4 592 |
4 592 |
5 665 |
|
-50.0 |
|
|
OCF, bln rub |
? |
|
8 168 |
11 384 |
9 072 |
9 072 |
8 006 |
|
12 162 |
|
CAPEX, bln rub |
? |
|
650.0 |
579.0 |
0.000 |
728.0 |
585.0 |
|
705.0 |
|
FCF, bln rub |
? |
|
7 518 |
10 805 |
9 072 |
8 344 |
7 421 |
|
12 397 |
|
Dividend payout, bln rub
|
|
|
3 449 |
3 605 |
0.000 |
3 709 |
3 809 |
|
5 886 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
3 875% |
57.9% |
0.00% |
80.8% |
67.2% |
|
-11 772% |
|
|
OPEX, bln rub |
|
|
10 190 |
10 609 |
14 294 |
10 650 |
13 013 |
|
13 533 |
|
Cost of production, bln rub |
|
|
4 572 |
6 601 |
5 657 |
5 657 |
5 968 |
|
39 113 |
|
R&D, bln rub |
|
|
5 039 |
5 363 |
4 977 |
4 977 |
6 923 |
|
5 661 |
|
Interest expenses, bln rub |
|
|
984.0 |
1 001 |
935.0 |
935.0 |
944.0 |
|
965.0 |
|
|
Assets, bln rub |
|
|
68 407 |
67 952 |
63 171 |
63 171 |
62 125 |
|
54 525 |
|
Net Assets, bln rub |
? |
|
18 221 |
21 064 |
0.000 |
21 209 |
22 833 |
|
18 474 |
|
Debt, bln rub |
|
|
31 402 |
26 695 |
0.000 |
25 230 |
24 987 |
|
23 249 |
|
Cash, bln rub |
|
|
7 910 |
7 829 |
7 630 |
7 630 |
7 264 |
|
5 037 |
|
Net debt, bln rub |
|
|
23 492 |
18 866 |
-7 630 |
17 600 |
17 723 |
|
18 212 |
|
|
Ordinary share price, rub |
|
|
58.3 |
72.6 |
85.9 |
85.9 |
81.0 |
|
81.7 |
|
Number of ordinary shares, mln |
|
|
1 257 |
1 256 |
1 255 |
1 255 |
1 248 |
|
1 247 |
|
|
Market cap, bln rub |
|
|
73 233 |
91 198 |
107 742 |
107 742 |
101 100 |
|
101 818 |
|
EV, bln rub |
? |
|
96 725 |
110 064 |
100 112 |
125 342 |
118 823 |
|
120 030 |
|
Book value, bln rub |
|
|
-23 013 |
-20 723 |
-37 208 |
-15 999 |
-11 935 |
|
-10 386 |
|
|
EPS, rub |
? |
|
0.07 |
4.96 |
3.66 |
3.66 |
4.54 |
|
-0.04 |
|
FCF/share, rub |
|
|
5.98 |
8.60 |
7.23 |
6.65 |
5.95 |
|
9.94 |
|
BV/share, rub |
|
|
-18.3 |
-16.5 |
-29.6 |
-12.7 |
-9.56 |
|
-8.33 |
|
|
EBITDA margin, % |
? |
|
16.7% |
41.5% |
24.8% |
32.4% |
38.7% |
|
0.48% |
|
Net margin, % |
? |
|
0.36% |
22.8% |
16.8% |
16.8% |
20.9% |
|
-0.17% |
|
FCF yield, % |
? |
|
10.3% |
11.8% |
8.42% |
7.74% |
7.34% |
|
12.2% |
|
ROE, % |
? |
|
0.49% |
29.6% |
|
21.7% |
24.8% |
|
-0.27% |
|
ROA, % |
? |
|
0.13% |
9.16% |
7.27% |
7.27% |
9.12% |
|
-0.09% |
|
|
P/E |
? |
|
822.8 |
14.7 |
23.5 |
23.5 |
17.8 |
|
-2 036 |
|
P/FCF |
|
|
9.74 |
8.44 |
11.9 |
12.9 |
13.6 |
|
8.21 |
|
P/S |
? |
|
2.97 |
3.34 |
3.95 |
3.95 |
3.73 |
|
3.54 |
|
P/BV |
? |
|
-3.18 |
-4.40 |
-2.90 |
-6.73 |
-8.47 |
|
-9.80 |
|
EV/EBITDA |
? |
|
23.4 |
9.72 |
14.8 |
14.2 |
11.3 |
|
863.5 |
|
Debt/EBITDA |
|
|
5.68 |
1.67 |
-1.13 |
1.99 |
1.69 |
|
131.0 |
|
|
R&D/CAPEX, % |
|
|
775.2% |
926.3% |
|
683.7% |
1 183% |
|
803.0% |
|
|
CAPEX/Revenue, % |
|
|
2.63% |
2.12% |
0.00% |
2.67% |
2.16% |
|
2.45% |
|
| Gilead Sciences shareholders |
